Aztreonam–Avibactam for Patients Who are Critically Ill with Gram-Negative Bacterial Infections: Comparison with Colistin Plus Meropenem Subgroup from the Phase 3 REVISIT Study
Year: 2026
Type: article
Abstract: INTRODUCTION: The phase 3 REVISIT trial evaluated aztreonam-avibactam versus meropenem ± colistin for complicated intra-abdominal infection (cIAI), hospital-acquired pneumonia (HAP), or ventilator-associated pneumonia (VAP). This descriptive post hoc analysis explored efficacy and safety of aztreonam-avibactam versus colistin plus meropenem in patients with cIAI or HAP/VAP. METHODS: This post hoc analysis included patients who received colistin plus meropenem (all with baseline Acute Physiology and Chronic Health Evaluation II [APACHE II] scores ≥ 8) and patients who received aztreonam-avibactam with baseline APACHE II scores ≥ 8, for comparable baseline severity. The primary efficacy endpoint was adjudicated clinical cure rate at the test-of-cure (TOC) visit in the intent-to-treat (ITT) and clinically evaluable (CE) analysis sets. Secondary endpoints included clinical cure rate at TOC by infection type, favorable microbiological response at TOC, 28-day mortality, and safety. Efficacy and safety outcomes were compared descriptively. RESULTS: Overall, we included 186 patients in the ITT population (aztreonam-avibactam, n = 160; colistin plus meropenem, n = 26). Clinical cure rates (95% CI) were 63.1% (55.5-70.3) and 53.8% (35.1-71.8) for aztreonam-avibactam and colistin plus meropenem, respectively (ITT). Results were similar in the CE analysis set. Clinical cure rates in both cIAI and HAP/VAP subgroups were consistent with the overall results, although 95% CIs were wide and the number of patients treated with colistin plus meropenem was small. Microbiological response rate was 71.7% for aztreonam-avibactam and 46.7% for colistin plus meropenem (microbiological ITT). Twenty-eight-day mortality was similar for aztreonam-avibactam (7.5%) and colistin plus meropenem (11.5%; ITT). Proportions of patients with all-cause adverse events (AEs) and serious AEs were generally similar in both groups, with fewer treatment-related AEs for aztreonam-avibactam. CONCLUSIONS: This exploratory post hoc analysis provides further insights into the efficacy and safety of aztreonam-avibactam versus colistin plus meropenem in patients with cIAI or HAP/VAP who were critically ill. CLINICAL TRIAL REGISTRATION: NCT number: NCT03329092.
Source: Infectious Diseases and Therapy
Institutions: Fudan University, Huashan Hospital, Tel Aviv Sourasky Medical Center, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Centro de Investigación Biomédica en Red Enfermedades Infecciosas, National and Kapodistrian University of Athens, Technion – Israel Institute of Technology, Rambam Health Care Campus, Shanghai Pulmonary Hospital, Pfizer (China), Pfizer (United States), Pfizer (United Kingdom), Pfizer (India)
Language: English
Subfield: Microbiology (medical)
Field: Medicine
Domain: Health Sciences
Keywords: aztreonam-avibactam, gram-negative bacterial infection, complicated intra-abdominal infections, nosocomial pneumonia, ventilator-associated pneumonia, critically ill patients, clinical cure rate, microbiological response, 28-day mortality, adverse events, drug safety, combination antibiotic therapy, APACHE II score, post hoc analysis
Open Access status: gold
Estimated APC paid: $7,400
OpenAlex ID: W7225895702
